Solanezumab for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 7 registered trials.

Why this status

  1. 6 Mar 2020: Trial completed, NCT04623242
  2. 10 Nov 2020: Trial registered, NCT04623242

The trials

NCT00329082: Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

State
Completed
Phase
Phase 2
People
25 taking part
Started
May 2006
Primary completion
May 2008
Arms
1, 2, 3, 4
Results
None posted
  1. 24 May 2006: Trial registered

NCT00749216: Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease

State
Completed
Phase
Phase 2
People
33 taking part
Started
Sep 2008
Primary completion
Jul 2009
Arms
QW, Q4W, Q8W
Results
None posted
  1. 9 Sep 2008: Trial registered

NCT01127633: Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

State
Stopped early
Phase
Phase 3
People
1,457 taking part
Started
Dec 2010
Primary completion
Jul 2014
Arms
Solanezumab
Results
Posted on the registry
  1. 21 May 2010: Trial registered
  2. 3 May 2018: Trial results posted

NCT01760005: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

State
Under way
Phase
Phase 2 and Phase 3
People
490 planned
Started
Dec 2012
Primary completion
Apr 2028
Arms
Solanezumab
Results
None posted
Papers
doi:10.1002/alz.70689, doi:10.1007/s00259-023-06209-0, doi:10.1016/s1474-4422(25)00024-9, doi:10.1101/2024.10.29.24316289
  1. 3 Jan 2013: Trial registered

NCT02614131: A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

State
Stopped early
Phase
Phase 1
People
50 taking part
Started
Dec 2015
Primary completion
Dec 2016
Arms
Solanezumab (Part C)
Results
Posted on the registry
  1. 25 Nov 2015: Trial registered
  2. 23 Sep 2019: Trial results posted

NCT04623242: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

State
Completed
Phase
Phase 2 and Phase 3
People
194 taking part
Started
Dec 2012
Primary completion
22 Nov 2019
Arms
Solanezumab
Results
Posted on the registry
Papers
doi:10.1001/jamaneurol.2024.0991, doi:10.1136/bmjno-2022-000335
  1. 6 Mar 2020: Trial completed
  2. 10 Nov 2020: Trial registered
  3. 22 Sep 2022: Trial results posted

How the status changed

  1. 16 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.